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Abstract: An important property of C60 in aquatic ecotoxicology is that it can form stable 
aggregates with nanoscale dimensions, namely nC60. Aggregation allows fullerenes to 
remain suspended for a long time, and the reactivity of individual C60 is substantially 
altered in this aggregate form. Herein, we investigated the interaction of nC60 and human 
serum album (HSA) using the methods of fluorescence, fluorescence dynamics, circular 
dichroism (CD), and site marker competitive experiments. We proposed a binding model 
consistent with the available experimental results for the interactions of nC60 with HSA. 
During the interaction process, the structure and conformation of HSA were affected, 
leading to functional changes of drug binding sites of HSA. 
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1. Introduction  
Since the discovery of fullerene (C60) in 1985 [1], concerns have been raised about the proposed 
applications of C60 and its derivatives in biology and pharmacology [2,3]. These potential applications 
include items as varied as antiviral, anticancer, or antioxidant agents [4], and drug delivery   
vehicles [5,6]. Despite the broad range of research focused on the application potential of fullerenes, 
their toxicological and environmental effects are still not well known [7]. With an octanol-water 
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partition coefficient log KOW of 6.67 and a solubility of less than 10
−9 mg/L, pristine fullerene is poorly 
soluble in water [8]. For C60 fullerene, its interaction with proteins has been poorly studied   
due in particular to its low solubility in water, and hence much research has focused on the interactions 
between its water-soluble derivatives and some proteins such as HIV protease [9,10], a fullerene-specific 
antibody [11], human serum albumin (HSA) [12] and bovine serum albumin (BSA) [13]. 
An important property of C60 in aquatic ecotoxicology is its acquisition of charge and ability to 
form relatively stable clusters (referred to as nC60) in aqueous systems, by means of natural processes 
like water flow and mixing, as well as by vigorous stirring in the laboratory [14–16]. Aggregation 
allows fullerenes to remain suspended for weeks or months [17], this aspect of nC60 may provide a 
more complete understanding of how it will behave in natural systems or in organisms.  
In previous work, BSA was found to adopt a more flexible conformational state on the boundary 
surface of gold nanoparticles as a result of the conformational changes in the bioconjugates [18]. It 
was also demonstrated that C60 nanoparticles can be stabilized by nonspecific adsorption of HSA and 
remain well dispersed even in the physiological environment [19]. Therefore, for further understanding 
of the transportation of nC60 fullerene in the bodies and the resulting related bio-effects, the interaction 
of nC60 fullerene with proteins is crucial and must be ascertained. In this study, the interaction between 
human serum albumin and nC60 in aqueous solution was investigated by fluorescence, fluorescence 
dynamics, circular dichroism (CD), and binding site marker competitive experiments. 
2. Results and Discussion  
2.1 The Fluorescence Quenching of HSA by nC60 
Quenching refers to any process which decreases the fluorescence intensity of a given substance.  
A variety of processes can result in quenching, such as excited state reactions, energy transfer, 
complex-formation and collisional quenching. Figure 1 shows the fluorescence spectra of HSA in the 
absence and the presence of nC60 in phosphate buffer with an excitation wavelength of 280 nm. HSA 
displayed the maximum emission at a wavelength of 343 nm. The fluorescence intensity of HSA 
decreased with increasing concentration of nC60 and the maximum emission wavelength was slightly 
red shifted. It is known that the shift of maximum emission wavelength corresponded to a polarity 
change around the chromophore residues. Red shift indicates that the microenvironment of fluorophors 
in HSA is changed after addition of nC60. Int. J. Mol. Sci. 2011, 12  
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Figure 1. Fluorescence spectra of human serum album (HSA) in the presence of nC60 
aggregates. HSA concentration was 20 μM. The concentration of C60 (from A to F) was 0, 
1.41, 2.83, 5.66, 8.48, and 11.30 μM, respectively (pH = 7.4; ex = 280 nm). 
 
2.2. Quenching Mechanism of nC60 to HSA 
For dynamic quenching, the quenching is an additional process that deactivates the excited state 
besides radiative emission through the collision between the quencher and fluorophore. As for HSA,  
the dependence of the emission intensity on quencher concentration  ] [Q   is given by the   
Stern-Volmer equation: 
] [ 1 ] [ 1 / 0 0 Q K Q K F F SV q + = + = τ   (1) 
where  F and F 0 are the fluorescence intensity in the absence and in the presence of quencher, 
respectively;  0 τ  is the lifetime of HSA; Kq is the bimolecular rate constant for the dynamic reaction of 
the quencher with the fluorophore; Ksv is called the Stern-Volmer constant. 
For static quenching, the binding of a quencher (Q ) to a protein (M ) can be described with the 
following reaction: 
n MQ M nQ ↔ +  
Then the binding constant (K ) is given by 
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The relation between the fluorescence intensity and concentration of quencher [Q ] is given by 
] [ ] [ ] [ 0 n MQ M M + =   (3)
n n Q K
M
MQ
M
M M
F
F F
] [
] [
] [
] [
] [ ] [ 0 0 = =
−
=
−
  (4)
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The quenching data were presented as a plot of 
F
F0  versus  ] [Q , and the Stern-Volmer plot is an 
upward curvature, concave towards the y-axis, as shown in Figure 2A. 
This result indicates that HSA can be quenched both by collisions and by complex formation with 
C60 nanoparticles. Then the fractional fluorescence remaining (
F
F0 ) is given by 
]) [ 1 (
0
Q K f
F
F
SV + =   (6) 
where  f   is the fraction not complexed, and  ]) [ 1 ( Q KSV + is the fraction not quenched by   
collisional encounters. 
According to the definition,  f can be obtained from Equation (5), and then rearrangement of 
Equation (6) yields: 
1 0 ] [ ] [ ] [ ) 1 (
+ + + = −
n
SV
n
SV Q K K Q K Q K
F
F   (7) 
The nonlinear fitting analysis was performed by plotting  ) 1 (
0 −
F
F  against Q (Figure 2B). From the 
Stern-Volmer plot, the value of KSV was 6.56 × 10
4 L·mol
−1. The 
q K  was easily calculated according 
to Equation (1), 6.56 × 10
12 L·mol
−1·s
−1, which is much higher than the maximal collided dynamic 
quenching constant (2.0 × 10
10 L·mol
−1·s
−1) [20]. This result indicates that the fluorescence quenching 
of HSA by the addition of nC60 is mainly caused by static quenching. There is   
non-linearity obtained from Stern-Volmer when the nC60 concentration is lower than 11.30 μM. When 
nC60 concentration is higher than 11.30 μM, the intrinsic fluorescence of HSA is significantly 
quenched. The plot appears to be an upward curvature with increasing nC60 concentration, which is a 
characteristic feature of mixed quenching.  This suggests that it is not a single quenching mechanism 
that exists in the binding process. The mechanism of HSA quenching caused by water-soluble pristine 
nC60 is different to that caused by water-soluble nC60 derivative [12]. 
Figure 2. (A) The Stern-Volmer plot for the fluorescence quenching of HSA by nC60;  
(B) Nonlinear fitting analysis performed by plotting (F0/F-1) against [Q]. 
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2.3. The Conformation Study of HSA 
Synchronous fluorescence spectroscopy is a common method used to provide information about 
conformational changes of protein since the possible shift of maximum emission wavelength is related 
to the polarity of the environment. The synchronous fluorescence spectra of HSA-nC60 system are 
shown in Figure 3. The maximum emission wavelength of tyrosine residues has a small red shift (from 
283 nm to 285 nm) when Δλ = 15 nm, indicating that there are some changes in the environment of the 
tyrosine residues. The maximum emission wavelength of tryptophan residues red shifts from 279.5 nm 
to 281.5 nm when Δλ = 60 nm (Figure 3B). This suggests that there is a less hydrophobic or more 
polar environment change around the tyrosine residues and tryptophan residues. This may be ascribed 
to the fact that the hydrophobic amino acid structure surrounding tryptophan residues in HSA tends to 
collapse slightly, resulting in tyrosine residues and tryptophan residues being more exposed to the 
aqueous phase. 
Figure 3. Synchronous fluorescence spectra of HSA in the presence of nC60.  
(A) Δλ = 15 nm; (B) Δλ = 60 nm. HSA concentration is 20 μM. The concentration of C60 
(from A to F) was 0, 1.41, 2.83, 5.66, 8.48, 11.30 μM, respectively. 
   
Circular dichroism spectra can sensitively monitor conformation changes in the protein upon 
interaction with the ligand. In this experiment, the calculated α-helicity content of native HSA solution 
is 54.9%, and with the addition of nC60 to the native HSA solution, the α-helicity content of HSA 
increased to 59.8%, 61.2% and 62.0% (Figure 4). Apparently, the higher the added nC60 concentration, 
the more the α-helicity content. The increase of α-helicity content indicated that the binding of HSA 
and nC60 induces protein folding, which results in some hydrophobic regions becoming more compact. Int. J. Mol. Sci. 2011, 12  
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Figure 4. The circular dichroism (CD) spectra of the HSA-nC60 system. Concentration  
of HSA was 7.3 μM; Concentration of nC60 (from A to D) was 0, 3.38, 5.63,   
11.8 μM, respectively. 
 
2.4. Interaction between HSA and nC60 
It is well known that HSA has two major drug binding sites, site I and site II, which are located in 
the hydrophobic pocket of sub-domain IIA and sub-domain IIIA, respectively. In order to identify the  
nC60-binding site on HSA, two probes were used. One probe of HSA is dansylamide (DNSA), whose 
binding site is located in the region of sub-domain IIA (sudlow site I); another probe, dansylproline 
(DP) is bound to HSA in the sub-domain IIIA (sudlow site II) [21,22]. During the experiment, nC60 
was gradually added to the solution of HSA with site probes held in equimolar concentrations   
(20  μM). No absorption of these two probes to nanoparticles of C60  was observed in capillary 
electrophoresis analysis (data not shown). As shown in Figure 5, only the probes or HSA alone have 
no fluorescence signal within the wavelengths 400–600 nm. When the probes and HSA are mixed 
together, the DNSA-HSA complex has a maximum emission wavelength at 487 nm (excitation 
wavelength 350 nm) and DP-HSA has a maximum emission wavelength at 480 nm (excitation 
wavelength 375 nm). With the addition of nC60 to the HSA-probe solution, the fluorescence intensity 
of the HSA-probe complex was significantly lower than that without nC60, indicating that the binding 
of DNSA/DP to HSA was affected by adding nC60. The fluorescence intensity of DNSA-HSA was 
lower than that of DP-HSA, indicating that nC60 could more strongly influence the binding of DNSA to 
HSA than that of NP to HSA.  Int. J. Mol. Sci. 2011, 12  
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Figure 5. Effect of nC60 on binding site probe-HSA system. Concentrations of HSA and 
probes (DNSA and DP) were 20 μM. (a) 1: HSA only; 2: DNSA only; Ex = 350 nm;  
(b) 1: HSA only, 2: DP only; ex = 375 nm. Concentrations of C60 (from 3 to 8) were 0, 
1.41, 2.83, 5.66, 8.48, 11.30 μM, respectively. The inserts correspond to the molecular 
structure of binding site probes. 
 
 
2.5. Representation of Interaction of HSA and nC60 
Our results above indicate that the fluorescence quenching and conformational changes of HSA can 
be attributed to the interaction between HSA and nC60. C60 fullerene has also been reported to be 
bound to the subdomain IIA of HSA using time-resolved fluorescence decay experiments, docking 
calculations, and binding site alignment methods [13,23]. Here we have employed several approaches 
in order to address the issue of fullerene interactions with proteins. What needs to be especially 
pointed out is that it is difficult to incorporate nC60 into the binding pocket because the size of nC60 is 
larger than protein molecules. The hydrodynamic diameter of the nC60 nanoparticles was determined to 
be from 50 nm to 110 nm by TEM and DLS, respectively (Figure 6A,B). Ganazzoli et al. reported Int. J. Mol. Sci. 2011, 12  
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atomistic computer simulations of some albumin subdomains on a hydrophobic graphite surface [24]. 
According to these simulations, we proposed a binding model to describe the interaction between HSA 
and nC60 (Figure 6C). In this model, HSA is adsorbed on the surface of nC60 aggregate which leads to 
the fluorescence quenching and conformational changes of HSA. The interaction sites were presumed 
to be near to Site I and Site II of HSA; following the structure and conformation of HSA was affected 
during adsorption. In our previous study, we have observed that HSA could compete for the surface of 
nC60 with functional enzymes [25].  
Figure 6. (A) Transmission electron microscopy (TEM)  image of nC60; (B) The mean 
hydrodynamic diameter of the nC60 measured by dynamic light scattering (DLS);   
(C) Schematic representation of HSA interacting with aggregate nC60 surface.  
   
 
3. Experimental 
3.1. Materials 
C60 (99.5% purity) was obtained from Sigma Chemical Company, St. Louis, USA. HSA (98% 
purity, essentially fatty acid and globulin free) was purchased from NEB (USA). All solutions were 
prepared in ultrapure water with the resistivity of 18.2 MΩ⋅cm (ALGA system, UK). Phosphate buffer 
(10 mM, pH = 7.4) was prepared with chemicals of analytical pure grade, obtained from commercial 
sources, and filtered with a 0.22-µmm filter (Millipore, Bedford, MA, USA). All other materials were 
of analytical pure grade. Int. J. Mol. Sci. 2011, 12  
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3.2. Preparation and Characterization of Water-Soluble nC60  
C60 suspensions were prepared according to the method described previously [26]. Ten milligrams 
of C60 was completely dissolved in 10 mL toluene. Then 2.5 mL C60 toluene solution was added into  
50 mL water. After ultrasonic treatment for approximately 4 h, toluene was allowed to evaporate under 
vacuum for at least 1 h. The mean hydrodynamic diameter of the nC60 nanoparticles was determined 
by transmission electron microscopy (TEM) and dynamic light scattering (DLS) (BI-20OSM laser 
light scattering spectrometer, Brookhaven, USA). 
3.3. Methods 
Absorption spectra were recorded on a UV-2102PCS UV-Vis spectrophotometer (UNICO, USA) 
equipped with a 1.0 cm quartz cuvette at room temperature. The wavelength range was recorded from 
200 to 500 nm. 
All fluorescence emission spectra were recorded in the range of 300–450 nm on a LS-55 
spectrofluorimeter (PE, USA) equipped with 100 µL quartz cells. The bandwidth of excitation and 
emission (3 nm) and scan speed (300 nm/min) were kept constant within each data set. Fluorescence 
intensity at 343 nm was used for calculation in Stern-Volmer equation. All measurements were 
performed at room temperature (~25 °C). 
Binding site marker competitive experiments were carried out by the fluorescence titration 
methods. The concentration of HSA and dansylamide/dansylproline (DNSA/DP) were all kept at   
10 μM. Then nC60 was gradually titrated into the HSA-DNSA/DP systems. Fluorescence spectra were 
recorded with an excitation wavelength of 370 nm (for DNSA) and 375 nm (for DNP) in the range of 
400–600 nm. 
Circular dichroism (CD) spectroscopy was performed on a J-810 spectropolarimeter (Jasco Co., 
Japan) over a wavelength of 200–260 nm. The scanning speed was set at 500 nm/min. Each spectrum 
was the average of three successive scans and appropriate buffer solutions running under the same 
conditions were taken as blank and their contributions were subtracted from the experimental spectra.  
4. Conclusions  
We observed a quenching of fluorescence of HSA in the presence of nC60, and fluorescence 
quenching mechanism was investigated by the Stern-Volmer equation which showed a characteristic 
feature for the combined fluorescence quenching. The binding of HSA to nC60 increases the polar 
environment of the Trp residue, resulting in a red shift in the fluorescence spectra. The CD results 
showed that the percentage of α-helicity of HSA increased, revealing that the protein becomes more 
compact upon association with nC60. The results indicate that the fluorescence quenching and 
conformational changes of HSA can be attributed to the interaction between HSA and nC60. In the 
binding site marker competitive experiment, the binding of DNSA/DP to HSA was affected by adding 
nC60. We propose that HSA interacted with aggregate nC60 surface, and led to the functional changes 
of drug binding sites of HSA. Int. J. Mol. Sci. 2011, 12  
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